French pharma major Sanofi today announced the appointment of Kathleen Tregoning as a new member of the executive committee, effective February 27, 2017. 30 January 2017
EMD Serono, the biopharmaceutical business of German pharma major Merck KGaA in the USA and Canada, has announced that Richard Smith has been appointed its head of US fertility and endocrinology. 25 January 2017
A major change at the top of GlaxoSmithKline’s pharmaceutical business has been announced as part of what has been described as ‘succession processes’ at the company. 19 January 2017
Bayer today announced the appointment of Dr Carsten Brunn as president of its pharmaceuticals business in the Americas, comprising the USA, Canada, Central and Latin America. 17 January 2017
The new man at the helm of Eli Lilly has started off his time as the US pharma major’s chief executive by announcing a series of organizational and leadership structure changes. 6 January 2017
Provectus Biopharmaceuticals has said that, on December 27, 2016, its board of directors unanimously voted to terminate Peter Culpepper, effective immediately, from all positions held with the company, including chief executive and chief operating officer. 30 December 2016
US fertility treatment specialist OvaScience lost nearly a third of its value after it announced major workforce cuts and the departure of two top executives. 22 December 2016
News that AstraZeneca was losing the experienced head of one its focus areas caused a slight share price wobble on Monday – but the company is confident that his shoes will be ably filled. 21 December 2016
Troubled Valeant Pharmaceuticals has announced the departure of three executives, as the business continues to restructure at the close of a punishing 2016. 14 December 2016
Effective February 1, 2017, Robert LaCaze will become executive vice president of the new Oncology Strategic Business unit at the Pharmaceuticals Division of German pharma major Bayer. 13 December 2016
A new man is at the helm of the European Federation of Pharmaceutical Industries and Association (EFPIA) after the departure of Richard Bergström. 12 December 2016
French pharma company Ipsen today announced that Claude Bertrand, executive vice president, R&D, chief scientific officer, will depart Ipsen on January, 2017, to join another company. 12 December 2016
Lisa Anson, president of AstraZeneca UK and Ireland, has been elected as the next president of trade group the Association of the British Pharmaceutical Industry (ABPI). 7 December 2016
Experienced industry executive Hervé Gisserot is to become head of pharmaceuticals for the newly-created Asia Pacific Region at UK pharma major GlaxoSmithKline. 22 November 2016
Immuno-oncology company PsiOxus Therapeutics may opt for an initial share offering in 2017, though the company is not looking to go public anytime sooner, chief executive John Beadle told The Pharma Letter in an exclusive interview. 4 November 2016
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024